Valion Bio, Inc.
VBIO· Nasdaq
VBIOValion Bio, Inc.
Filed Aug 14, 2023 · 10-Q · 45 days after period end · 0000950170-23-042520
| Metric | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|
| Revenue | $161.00K | $528.00K | $268.00K |
| Net Income | -$2.13M | -$3.02M | -$1.09M |
| EPS Diluted | -$7.16 | -$0.32 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end
